Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

NCT00848926 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00848926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00848926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
May 31, 2015
Enrollment
102 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

disease, hodgkin